MĀNUKA PERFORMANCE LIMITED
An Advanced Bioactive Nutrition Company · New Zealand
01
The Problem
WHAT PROBLEM
ARE WE
SOLVING?
MILLIONS OF PEOPLE.
NO SOLUTION.
Three large, urgent, and underserved nutritional gaps exist right now — and no single company is addressing all three with validated, science-backed products.
31M
Americans currently on GLP-1 weight-loss drugs — eating far less, with documented protein, fibre and micronutrient deficits. No dedicated nutrition system exists for them.
550K
US marathon finishers annually seeking clean, natural, science-verified energy and recovery — a premium segment poorly served by mass-market sports nutrition.
$4.5B
US gut health supplement market — yet consumers and clinicians alike struggle to find products with independently verified bioactive profiles they can actually trust.
02
The Product
HOW UNIQUE
IS WHAT
WE HAVE?
NOBODY ELSE
HAS THIS.
NOBODY CAN.
Our products are built on PolySure™ — a proprietary 7-polyphenol bioactive system derived from New Zealand's native honey varieties: Mānuka, Rewarewa, Kāmahi, Tāwari, Pōhutukawa, and Rātā. Geographically irreplaceable. Independently verified to ISO-17025. Exclusive sourcing. Physician-led commercial channels. The combination of NZ indigenous provenance, clinical science, and a physician co-president in the US market is not replicable. Not in 12 months. Not in five years.
7
Polyphenols tracked per batch — ISO-17025 verified. Certificate of Analysis on every production run. No competitor does this.
6+
Native NZ honey varieties — geographically protected, genetically unique, exclusively sourced. The raw material cannot be manufactured elsewhere.
1
Physician co-president in the US with active telehealth prescriber networks — the clinical credibility channel competitors cannot buy their way into.
03
The Upside
HOW BIG
CAN THIS
GET?
THREE MARKETS.
$28B+ COMBINED
US OPPORTUNITY.
We are entering three US markets simultaneously — each large, each growing, each with a defensible first-mover position available. Capital raised now funds the channel build that locks in that position before the window closes.
$18B
US sports nutrition TAM · SAM $3.2B premium endurance · SOM $8–15M (5yr)
$4.5B
US gut health supplement TAM · SAM $1.2B bioactive-led · SOM $4–8M (5yr)
$6B
US GLP-1 companion nutrition TAM (2027 est.) · SAM $2.4B · SOM $20–40M (5yr)
Y2
EBITDA positive · 60% gross margin · No bridge round required · Single raise finances to profitability
Full materials available · NDA required to proceed
This document contains no financial projections or commercially sensitive data. Detailed investor brief, financial model, and clinical data available to qualified investors under executed NDA.